TG Therapeutics publishes data showing BRIUMVI reduced MS relapses by 56.7%
Tweet Send to a Friend
TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


